Puerarin (Isoflavone C-Glycoside · Cerebrovascular · Alcohol Metabolism)

Compound	Puerarin
Chemical class	Polyphenol — Isoflavone C-Glycoside (Daidzein-8-C-glucoside)
CAS	3681-99-0
Primary source	Pueraria lobata (kudzu root), Pueraria thomsonii
Key applications	Cerebral blood flow, cardiovascular, alcohol metabolism
Claim strength	Moderate
Typical form	Puerarin 98% isolate; Puerarin 40% kudzu extract
Buy from Herbuno	Puerarin 98% Powder (Kudzu) | High-Purity Isolate | Pueraria lobata → Puerarin 40% Powder (Kudzu Extract) | Standardized Pueraria lobata →

Name origin: Directly from Pueraria genus (kudzu / ge gen). Puerarin is the primary isoflavone in kudzu root and its defining bioactive marker compound. Unlike most isoflavone glycosides (O-glycosides), puerarin is a C-glycoside — the glucose is bonded directly to the carbon of the isoflavone ring (C-8 position), conferring acid stability and resistance to gut microbial hydrolysis. Traditional use: Kudzu root (Ge Gen) is one of the 50 fundamental herbs in TCM, used for cervical muscle stiffness, fever, diarrhoea, alcohol hangover, hypertension, and angina. Intravenous puerarin preparations have been used in Chinese hospitals for ischaemic stroke and cardiovascular applications. Research trajectory: Puerarin has a substantial evidence base from Chinese clinical research including IV administration for cardiovascular and cerebrovascular conditions. Oral supplement research is growing, particularly for cardiovascular, metabolic, and alcohol metabolism applications. Commercial source: Puerarin is commercially available as a high-purity isolate (98% HPLC) and as a standardised kudzu (Pueraria lobata) root extract (40% puerarin) — one of the most widely available isoflavone C-glycosides. See sourcing options below.

---

Evidence for Puerarin Applications

Cerebrovascular and cardiovascular protection: Multiple Chinese clinical studies (including small RCTs) demonstrate IV puerarin improves cerebral blood flow, reduces ischaemic neurological deficit scores, and improves cardiac function in post-MI patients. Oral puerarin supplementation shows blood pressure reduction and endothelial function improvement in human studies. Meta-analyses of Chinese clinical literature support cardiovascular utility, though study quality varies. Claim strength: Moderate.

Alcohol metabolism support: Puerarin activates ALDH-2 (alcohol dehydrogenase pathway) and reduces blood acetaldehyde levels in animal and human studies. Human pilot RCTs show reduced alcohol consumption and improved next-day recovery with kudzu extract (puerarin-containing) taken before drinking. Mechanism is complementary to but distinct from daidzin’s ALDH-2 inhibition. Claim strength: Moderate.

Metabolic and bone health: Puerarin activates PPAR-γ and adiponectin pathways, improving insulin sensitivity in animal models of type 2 diabetes. Bone-protective effects via ER-mediated osteoblast stimulation are documented in ovariectomised animal models. Human metabolic data are limited. Claim strength: Moderate (animal convergent; limited human).

---

Dosage & Formulator Specification

Oral supplement range: 100–600 mg/day puerarin (as isolate) or 500–2000 mg/day kudzu root extract (40% puerarin). Chinese clinical studies typically use higher doses; oral bioavailability of puerarin is approximately 10–25%, lower than O-glycoside isoflavones due to the C-glycoside bond resisting gut hydrolysis to the free aglycone.

Herbuno’s Puerarin 98% allows precise puerarin dosing for premium applications. The Puerarin 40% extract provides puerarin alongside daidzin and other kudzu isoflavones for a full-spectrum kudzu formulation. For alcohol management applications, the full kudzu isoflavone profile (puerarin + daidzin) may be superior to puerarin alone based on mechanism complementarity.

Puerarin is water-soluble (superior to most isoflavone aglycones due to C-8 glucose). Stable at acidic pH; the C-glycoside bond is resistant to acid hydrolysis, differentiating it from O-glycosides. Compatible with aqueous beverage formats. Light-sensitive; amber packaging recommended for finished products.

---

Frequently Asked Questions — Puerarin

What makes puerarin’s C-glycoside structure significant?
C-glycosides have the sugar bonded directly to the carbon of the aglycone, unlike O-glycosides where the bond is oxygen-mediated. C-glycosides are resistant to acid hydrolysis and many gut microbial hydrolases, meaning puerarin is absorbed primarily as the intact glycoside rather than as the free aglycone daidzein. This gives it a distinct pharmacokinetic profile from daidzin (O-glycoside) and daidzein.

Is the IV puerarin evidence from Chinese hospitals applicable to oral supplement formulations?
The IV evidence establishes strong mechanistic and pharmacodynamic plausibility for puerarin’s cardiovascular effects. Oral translation requires bioavailability adjustment: IV 100 mg puerarin is not equivalent to oral 100 mg due to ~10–25% oral bioavailability. For oral supplement claims, reference oral study data where available and apply appropriate bioavailability context to IV study findings.

Can puerarin be combined with CoQ10 or omega-3 for a cardiovascular formulation?
Yes, and this is a rational combination. Puerarin (endothelial function, cerebral blood flow) + CoQ10 (mitochondrial energy, cardiac function) + omega-3 (anti-inflammatory, triglyceride reduction) address complementary cardiovascular mechanisms. No adverse interactions between these ingredients are documented.

Is kudzu root classified as a novel food in any regulated markets?
Kudzu root has a long history of use as a food ingredient in Japan, China, and other Asian markets. In the EU, it may require Novel Food assessment depending on the extract concentration and intended use level. In the US, kudzu root preparations are generally marketed as dietary supplements without novel food concerns. Formulators should verify regulatory status in their specific target markets.

---

Claim-strength scale – High = multiple human RCTs; Moderate = limited trials or strong preclinical convergence; Emerging = early-stage lab or animal data.

← HerbIQ Compound Index · HerbIQ P02: Extraction · HerbIQ P03: Delivery